Value proposition

From autism to ALS—redefining neurological care with science-driven, patient-focused therapies

Curemark is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for neurological and developmental disorders. Our diverse pipeline spans multiple critical areas of unmet need, including Autism Spectrum Disorder (ASD), Amyotrophic Lateral Sclerosis (ALS), Addiction, Attention-Deficit/Hyperactivity Disorder (ADHD), Schizophrenia, and Parkinson’s Disease.

At the heart of our mission is a commitment to addressing the root causes of these conditions, not just managing symptoms. Our lead investigational therapy targets key enzyme deficiencies associated with autism, offering a novel approach to treatment for a condition that affects millions worldwide.

Our pipeline reflects a science-driven, patient-first approach with a focus on discovering and developing transformative therapies for complex neurological conditions. By exploring the role of enzymes and their impact on brain function, Curemark aims to deliver targeted, effective treatments that improve patient outcomes.

With a commitment to scientific excellence, strategic collaboration, and a deep focus on patient well-being, Curemark is reshaping the future of neurological care. Our goal is to offer life-changing solutions for individuals living with autism, ALS, addiction, ADHD, schizophrenia, Parkinson’s disease, and other challenging conditions.

Stay connected with us as we continue to push the boundaries of discovery and bring new hope to patients, families, and caregivers. For more information, visit Curemark.com.

autism, neuro-developmental disorders, neurodegenerative disorders, enzymes, enzyme deficiencies, Autism Spectrum Disorder, CM-AT, ALS, Amyotrophic lateral sclerosis, addiction, Schizophrenia, Parkinson’s Disease, ADHD, and Attention-deficit/hyperactivity disorder